Best Biotech Stocks For 2019

Investment company Wechter Feldman Wealth Management, Inc. buys SPDR Select Sector Fund – Utilities, Vanguard Total Stock Market, SPDR Series Trust S&P Biotech, Berkshire Hathaway Inc, Vanguard Total Bond Market, sells iShares Core S&P Mid-Cap, iShares Russell Mid-cap Value, Vanguard High Dividend Yield ETF – DNQ, iShares Russell 1000 Value, Vanguard Mid-Cap ETF – DNQ during the 3-months ended 2017-06-30, according to the most recent filings of the investment company, Wechter Feldman Wealth Management, Inc.. As of 2017-06-30, Wechter Feldman Wealth Management, Inc. owns 27 stocks with a total value of $124 million. These are the details of the buys and sells.

New Purchases: XLU, XBI, BRK.B, Added Positions: VTI, IWV, TIP, AGG, IWB, OEF, IVV, VIG, BND, JNJ, Reduced Positions: T, XOM, GE, Sold Out: IJH, IWS, VYM, IWD, VO, VTV, VB, IJR,

For the details of Wechter Feldman Wealth Management, Inc.’s stock buys and sells, go to

Best Biotech Stocks For 2019: 2U, Inc.(TWOU)

Advisors’ Opinion:

  • [By David Kretzmann]

    Since its IPO in March 2014, 2U (NASDAQ:TWOU) stock is up over 160% as the company forges partnerships with famous schools, including Georgetown, Yale, Berkeley, and New York University.

Best Biotech Stocks For 2019: EnLink Midstream Partners, LP(ENLK)

Advisors’ Opinion:


    EnLink Midstream Partners (ENLK) is sponsored by independent oil and gas exploration giant Devon Energy (DVN), the owner of this acreage.

    These basins offer superior economics and EnLink’s close relationship with Devon provides leveraged exposure to the upstream operator’s accelerating activity in these plays.

Best Biotech Stocks For 2019: Allstate Corporation (The)(ALL)

Advisors’ Opinion:

  • [By Anders Bylund, Chuck Saletta, and Brian Feroldi]

    Read on to see why they pickedAllstate(NYSE:ALL),EPAM Systems(NYSE:EPAM), andUniversal Display(NASDAQ:OLED).

    Image source: Getty Images.

  • [By Michael Flannelly]

    Wells Fargo analysts see a number of upside catalysts for The Allstate Corporation (ALL), plus a positive trend for automobile insurers as a whole. As such, the analysts upgraded the insurance provider on Thursday.

    The analysts upgraded ALL from “Market Perform” to “Outperform” and boosted its valuation range from $48-$52 to $58-$62. This new valuation range suggests a 16% to 24% upside to the stock’s Wednesday closing price of $50.11.

    “We are upgrading the shares of Allstate to Outperform from Market Perform on the basis of several fundamental reasons unique to the company as well as several positive, emerging structural trends for auto insurers in general,” Wells Fargo analyst John Hall stated. “We do not believe that the market has yet paid for potential unit growth within Allstate’s branded standard book of auto insurance, something we envision occurring over the next 6-12 months.”

    As for some of the positive personal auto insurance sector trends, Hall noted, “These would include shifting demographics toward a safer driving population mix (more old drivers and fewer young drivers), changing driving habits particularly among millennials, a safer U.S. personal auto fleet, rising car sales pointing to positive symbol shift as well as industry conditions encouraging market share consolidation.”

    Wells Fargo boosted Allstate’s 2013 EPS estimates from $4.62 to $4.85 and 2014 EPS estimates from $4.85 to $5.20.

    Allstate shares were mostly flat during pre-market trading on Thursday. The stock is up 24.74% year-to-date.

  • [By Shauna O’Brien]

    Credit Suisse reported on Thursday that it has raised its estimates on insurance company The Allstate Corporation (ALL).

    The firm has raised its price target on ALL to $62. This price target suggests a 16% upside from the stock’s current price of $52.23. Analysts currently have an “Outperform” rating on ALL.

    Credit Suisse has also boosted estimates on ALL as its management is increasing returns.

    Allstate shares were up 32 cents, or 0.62%, during Thursday morning trading. The stock is up 30% YTD.

Leave a Reply

Your email address will not be published. Required fields are marked *